InMed Pharmaceuticals Inc. filed a Form 425 communication on November 2, 2026, announcing a planned 10-for-1 share consolidation of its Common Shares in connection with the proposed merger involving Mentari Therapeutics, Inc.
Key Highlights
- Consolidation ratio: One (1) post-consolidation Common Share for each ten (10) pre-consolidation Common Shares, as disclosed in the filing.
- Share count reduction: According to the filing, issued and outstanding Common Shares would be reduced from 5,493,735 to approximately 549,374 on a non-diluted basis, prior to the Merger taking effect.
- Board approval obtained: The filing states the Consolidation was approved by the Company's Board of Directors under the Business Corporations Act (British Columbia) and does not require separate shareholder approval for the Consolidation itself.
- Shareholder vote required: The Company disclosed it will proceed with the Consolidation only if shareholders approve three specified proposals at the annual general and special meeting scheduled for November 4, 2026.
- Expected trading date: The filing states post-consolidation Common Shares are anticipated to begin trading on the Nasdaq Capital Market on a consolidation-adjusted basis at market open on November 5, 2026, under new CUSIP 457637809 and ISIN CA4576378091.
- Underlying merger: The filing relates to an Agreement and Plan of Merger and Reorganization dated May 19, 2026, involving InMed, two merger subsidiaries, and Mentari Therapeutics, Inc.
InMed Discloses Share Consolidation Details Ahead of November 4 Shareholder Vote
According to the filing, NASDAQ:INM disclosed the planned share consolidation in a communication published November 2, 2026, stating that the action is being undertaken in connection with the previously announced merger with Mentari Therapeutics, Inc. The Merger Agreement, dated May 19, 2026, contemplates a two-step structure in which Indigo Merger Sub Corp. would first merge with and into Mentari, with Mentari surviving as a wholly owned subsidiary of InMed, followed immediately by Mentari merging with and into Indigo Merger Sub II, LLC.
The filing states that the Consolidation would leave each shareholder holding "the same percentage of Common Shares outstanding immediately after the Consolidation as such shareholder held immediately prior to the Consolidation." The exercise price and number of Common Shares issuable under outstanding stock options, warrants, and other convertible securities would be proportionately adjusted to reflect the Consolidation, according to the filing. The filing also notes that fractional shares resulting from the Consolidation would be rounded up if 0.5 or greater and down if less than 0.5, with no cash or other consideration paid for rounding, consistent with BCBCA requirements.
The filing indicates the Company's Form S-4 registration statement, which includes a proxy statement and prospectus as well as a management information circular, was declared effective by the SEC on October 1, 2026. The communication notes that the forward-looking statements it contains, including those about the timing and completion of the Consolidation and the Merger, are subject to risks and uncertainties as described in InMed's cautionary language and regulatory filings.
What Was Disclosed
InMed Pharmaceuticals filed a Form 425 on November 2, 2026, disclosing a planned 10-for-1 share consolidation tied to its proposed merger with Mentari Therapeutics. The consolidation is conditional on shareholder approval of three proposals at the November 4, 2026 meeting.




Please wait processing your request...